Baseline characteristics of DLBCL patients in a PET+ PR before autologous transplantation
. | No ECF . | ECF . | P . |
---|---|---|---|
No. of patients | 67 | 182 | |
No. of centers | 39 | 64 | |
Patient age | |||
Μedian (range), y | 63 (39-77) | 57 (20-76) | <.001 |
≥65 y, n (%) | 29 (43.3) | 47 (25.8) | |
Males | 38 (56.7) | 106 (58.2) | .83 |
Patient race | .20 | ||
White | 56 (83.6) | 134 (73.6) | |
African American | 7 (10.4) | 34 (18.7) | |
Other* | 4 (6) | 9 (4.9) | |
Missing data | 0 | 5 (2.8) | |
Karnofsky performance score | |||
≥90 | 32 (47.8) | 94 (51.6) | .83 |
Missing data | 2 (3) | 4 (2.2) | |
Disease at diagnosis | |||
Stage III-IV | 36 (53.7) | 135 (74.2) | .003 |
Missing data | 5 (7.5) | 14 (7.7) | |
LDH | |||
Elevated at diagnosis | 9 (13.4) | 24 (13.2) | .14 |
Missing data | 45 (67.2) | 100 (54.9) | |
Lines of therapy prior to HCT, median (range), n | 2 (1-5) | 2 (1-5) | .65 |
Bone marrow involvement at diagnosis | |||
No | 52 (77.6) | 143 (78.6) | .53 |
Missing data | 7 (10.4) | 12 (6.6) | |
Extranodal involvement at diagnosis | |||
Yes | 31 (46.3) | 105 (57.7) | .24 |
Missing data | 7 (10.4) | 12 (6.6) | |
Time from diagnosis to HCT, median (range), mo | 35 (16-149) | 11 (3-146) | <.001 |
Residual nodal bulk at HCT | .18 | ||
Nonbulky (<5 cm) | 24 (35.8) | 87 (47.8) | |
Bulky (≥5 cm) | 7 (10.5) | 22 (12.1) | |
Not reported | 36 (53.7) | 73 (40.1) | |
Conditioning regimen | .88 | ||
BEAM | 55 (82.1) | 147 (80.8) | |
Bu/Cy | 7 (10.4) | 23 (12.6) | |
CBV | 5 (7.5) | 12 (6.6) | |
Primary refractory after first line of therapy | 0 | 144 (79.1) | <.001 |
Follow-up of survivors, median (range), mo | 69 (5-123) | 53 (10-149) |
. | No ECF . | ECF . | P . |
---|---|---|---|
No. of patients | 67 | 182 | |
No. of centers | 39 | 64 | |
Patient age | |||
Μedian (range), y | 63 (39-77) | 57 (20-76) | <.001 |
≥65 y, n (%) | 29 (43.3) | 47 (25.8) | |
Males | 38 (56.7) | 106 (58.2) | .83 |
Patient race | .20 | ||
White | 56 (83.6) | 134 (73.6) | |
African American | 7 (10.4) | 34 (18.7) | |
Other* | 4 (6) | 9 (4.9) | |
Missing data | 0 | 5 (2.8) | |
Karnofsky performance score | |||
≥90 | 32 (47.8) | 94 (51.6) | .83 |
Missing data | 2 (3) | 4 (2.2) | |
Disease at diagnosis | |||
Stage III-IV | 36 (53.7) | 135 (74.2) | .003 |
Missing data | 5 (7.5) | 14 (7.7) | |
LDH | |||
Elevated at diagnosis | 9 (13.4) | 24 (13.2) | .14 |
Missing data | 45 (67.2) | 100 (54.9) | |
Lines of therapy prior to HCT, median (range), n | 2 (1-5) | 2 (1-5) | .65 |
Bone marrow involvement at diagnosis | |||
No | 52 (77.6) | 143 (78.6) | .53 |
Missing data | 7 (10.4) | 12 (6.6) | |
Extranodal involvement at diagnosis | |||
Yes | 31 (46.3) | 105 (57.7) | .24 |
Missing data | 7 (10.4) | 12 (6.6) | |
Time from diagnosis to HCT, median (range), mo | 35 (16-149) | 11 (3-146) | <.001 |
Residual nodal bulk at HCT | .18 | ||
Nonbulky (<5 cm) | 24 (35.8) | 87 (47.8) | |
Bulky (≥5 cm) | 7 (10.5) | 22 (12.1) | |
Not reported | 36 (53.7) | 73 (40.1) | |
Conditioning regimen | .88 | ||
BEAM | 55 (82.1) | 147 (80.8) | |
Bu/Cy | 7 (10.4) | 23 (12.6) | |
CBV | 5 (7.5) | 12 (6.6) | |
Primary refractory after first line of therapy | 0 | 144 (79.1) | <.001 |
Follow-up of survivors, median (range), mo | 69 (5-123) | 53 (10-149) |
Unless otherwise noted, data are n (%).
BEAM, carmustine, etoposide, cytarabine and melphalan; Bu/Cy, busulfan/cyclophosphamide; CBV, cyclophosphamide, carmustine, and etoposide; LDH: lactate dehydrogenase.
No ECF: 3 Asian and 1 Native American. ECF: 7 Asian, 1 Pacific Islander, and 1 Native American.